Wells Fargo Downgrades Viridian Therapeutics(VRDN.US) to Hold Rating, Cuts Target Price to $27
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target
Buy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED Treatment
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $47
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
